caa a22 4500 445796669 CHVBK 20180317145127.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s10620-011-1583-4 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1583-4 Acid-Suppressive Effect of Rabeprazole 5mg and 10mg Once Daily by 24-Hour Esophageal pH Monitoring in Patients with Non-erosive Reflux Disease in Japan: A Multicenter, Randomized, Parallel-Group, Double-Blind Pharmacodynamic Study [Elektronische Daten] [Kiyoshi Ashida, Yoshikazu Kinoshita, Michio Hongo] Background: Acid suppression induced by rabeprazole 5mg in patients with NERD has not been reported in the literature. Aims: The objective of this study was to investigate gastroesophageal acid suppression in NERD patients by rabeprazole 5mg and 10mg/day. Methods: Subjects were grade M (minimal changes) NERD patients. Twenty-two patients not responding to open label antacid therapy entered a double-blind treatment phase in which rabeprazole 5mg or 10mg/day for four weeks were compared. Twenty-four-hour esophageal pH monitoring was performed before and on treatment (at week 4) to assess the pharmacodynamic effect of these doses of rabeprazole. Results: The frequency of heartburn episodes and the number of acid reflux episodes in the esophagus corresponded well in grade M NERD patients (r=0.44, P=0.042). Median percentage of time at pH<4 was 4.3% before treatment and 1.1% on treatment with rabeprazole 5mg (change from baseline; −2.5%), whereas the median percentage of time at pH<4 in the rabeprazole 10mg group was 7.4% before treatment and 0.5% on treatment (change from baseline; −6.6%). Likewise, treatment-related changes of median number of reflux episodes were −18.0 with rabeprazole 5mg and −44.0 with rabeprazole 10mg. For each esophageal pH data, no significant differences were observed between the two groups (P=0.377, P=0.077). Conclusions: Administration of 5 mg and 10mg rabeprazole sufficiently inhibited pathological gastroesophageal acid reflux and relieved heartburn episodes in NERD patients who did not respond to an antacid. Further investigation would be necessary to determine proper usage of the two doses. Springer Science+Business Media, LLC, 2011 24-hour esophageal pH monitoring nationallicence Rabeprazole nationallicence Nonerosive reflux disease nationallicence Minimal changes nationallicence Ashida Kiyoshi Division of Gastroenterology and Hepatology, Saiseikai Nakatsu Hospital, Osaka, Japan aut Kinoshita Yoshikazu Second Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan aut Hongo Michio Departments of Comprehensive Medicine and Psychosomatic Medicine, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba, 980-8574, Sendai, Miyagi, Japan aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/8(2011-08-01), 2333-2342 0163-2116 56:8<2333 2011 56 10620 https://doi.org/10.1007/s10620-011-1583-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1583-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ashida Kiyoshi Division of Gastroenterology and Hepatology, Saiseikai Nakatsu Hospital, Osaka, Japan aut NATIONALLICENCE 700 1- Kinoshita Yoshikazu Second Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan aut NATIONALLICENCE 700 1- Hongo Michio Departments of Comprehensive Medicine and Psychosomatic Medicine, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba, 980-8574, Sendai, Miyagi, Japan aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/8(2011-08-01), 2333-2342 0163-2116 56:8<2333 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer